Adding Retifanlimab To First-Line Chemotherapy for Patients with Advanced Squamous Cell Anal Cancer By Ogkologos - July 15, 2025 607 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the POD1UM-303/InterAACT-2 study Source RELATED ARTICLESMORE FROM AUTHOR Antitumour Activity of Rezatapopt Provides Proof of Concept for p53 Reactivation in Patients with TP53 Y220C-mutated Solid Tumours Rare Disease Day 2026: Advancing equity for people living with rare cancers in Europe EMA Recommends Extension of Therapeutic Indications for Ponatinib MOST POPULAR FDA Grants Accelerated Approval to Adagrasib for KRAS G12C-Mutated NSCLC December 16, 2022 EMA Recommends Extension of Indications for Durvalumab in the Management of... October 25, 2023 A Personalised Prediction Model Based on Clinical and Genomic Data Outperforms... September 2, 2021 Similar Efficacy Between Subcutaneous and Intravenous Pembrolizumab Given with Chemotherapy for... April 14, 2025 Load more HOT NEWS Patient Guide in Colorectal Cancer Now Available in Bulgarian ESMO World Congress on Gastrointestinal Cancer 2021, 30 June – 3... Happy Nurses Month! Mohs Surgery for Skin Cancer: What to Know and What to...
